Today we reported our second quarter 2024 financial results and provided a summary of recent corporate achievements and upcoming milestones. Learn more: https://bit.ly/4ck9oqs
Alumis
Biotechnology Research
South San Francisco, California 4,461 followers
Transforming the lives of patients living with immune-mediated diseases using a precision approach.
About us
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
- Website
-
https://www.alumis.com
External link for Alumis
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
611 Gateway Blvd
Suite 820
South San Francisco, California 94080, US
Employees at Alumis
-
Derrick Richardson
C-Suite Executive | Servant Leader | Mentor | Speaker | Change Agent | Advocate for the Underrepresented
-
William Coble
Transforming Quality Systems through Quality Intelligence
-
Vince Barella
-
Denise Winn, CPA (inactive)
Experienced Accounting and Finance Professional
Updates
-
Today we announced that patient dosing has commenced in the ONWARD Phase 3 clinical program evaluating ESK-001, an oral #TYK2 inhibitor, in moderate-to-severe Plaque #psoriasis. Topline data anticipated in 2026. Learn more: https://bit.ly/4c2rSvs
-
We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed
🧬 Transform therapies, reimagine lives. That’s exactly what Alumis does. 🌟 $ALMS is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies. 👏 In celebration of their listing on Nasdaq, Alumis joins us for the Opening Bell. Exciting! Stay tuned for more!
-
Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed
-
Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024
-
Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay
-
This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024
-
As #LupusAwarenessMonth comes to a close, we're inspired by the resilience and strength of the #lupus community. At Alumis, we're honored be part of the research community dedicated to advancing effective treatment options for people living with lupus. We recognize the global impact of lupus and will continue to focus on the advancement of our lupus clinical program with the goal of make a difference for the lupus community worldwide! #LupusAwareness #LupusResearch
-
Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw
Women are disproportionately affected by lupus. Black/African American and Hispanic/Latino/a/x/e women are 2-3x more likely than white women to develop #lupus and have more severe symptoms. #ManyOneCan learn more about #lupusresearch: https://lnkd.in/esmUVvvw #LupusAwarenessMonth
-
At Alumis, our aim is clear: to make a tangible difference for the #lupus community. This #LupusAwarenessMonth, we recognize the dedication of our employees who have devoted their careers to understanding this challenging disease as researchers, clinicians, and patient advocates. We are putting on purple – the color of Lupus Awareness Month – to raise awareness and drive forward clinical research so everyone with lupus can envision a brighter future! #LupusResearch #MakeLupusVisible